In context
Efpeglenatide was tested in a large randomised trial involving people with type 2 diabetes and cardiovascular disease or kidney disease plus additional risk factors. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- A cardiovascular-outcomes trial in a selected high-risk population does not establish the same outcomes in healthy people or for other formulations.
How to interpret this evidence
A cardiovascular-outcomes trial in a selected high-risk population does not establish the same outcomes in healthy people or for other formulations. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. pubmed.ncbi.nlm.nih.gov